ArticleAmerican journal of translational research2025
Enhanced efficacy of bisoprolol and digoxin combination in elderly patients with atrial fibrillation.
Article in American journal of translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo investigate the effect of combining bisoprolol and digoxin on cardiac function in elderly patients with atrial fibrillation (AF).
methodsA retrospective analysis was conducted on the clinical records of 100 elderly AF patients treated at the Second Affiliated Hospital of Hainan Medical University from April 2020 to April 2023. Forty-six patients treated with digoxin alone were assigned to the control group, while the remaining 54 patients treated with bisoprolol in addition to digox comprised the study group. Outcome measures included cardiac function-associated indices (left ventricular end-diastolic dimension (LVEDD), left ventricular end-systolic diameter (LVESD) and left ventricular ejection fraction (LVEF)), ventricular rate at rest and during exercise, myocardial energy metabolism (plasma N-terminal pro-B-type natriuretic peptide (NT-proBNP) and creatine kinase (CK)), and psychological status prior to and post therapy, and the overall response rate and adverse reactions. Multiple logistic regression was performed to identify independent risk factors for an unfavorable prognosis.
resultsAfter treatment, LVEDD and LVESD levels significantly dropped in both groups (P<0.01), and LVEF level increased significantly (P<0.001), especially in the study group (P<0.01). Ventricular rate at rest and during exercise also decreased significantly in both groups (P<0.001), with a more pronounced effect in the study group (P<0.001). NT-proBNP and CK levels greatly decreased in both groups (P<0.001), especially the study group (P<0.001). The study group presented a notably higher overall response rate compared to the control group (P=0.011), but no significant inter-group difference was observed in the total incidence of adverse reactions (P=0.547). Both groups showed significant reductions in SAS and SDS scores after treatment (P<0.05), with a more substantial improvement in the study group (P<0.05). Logistics regression analysis identified comorbid diabetes mellitus (P=0.025; OR=6.086; 95% CI=1.250-29.638), comorbid hypertension (P=0.007; OR=7.059; 95% CI=1.728-28.842), New York Heart Association classification (P=0.023; OR=0.197; 95% CI=0.049-0.800), and treatment modality (P=0.020; OR=5.911; 95% CI=1.326-26.338) as independent risk factors for unfavorable prognosis.
conclusionIn contrast to digoxin alone, combined application of bisoprolol and digoxin is more effective in treating elderly AF patients. The combined treatment can significantly improve LVEDD, LVESD, LVEF, and ventricular rate without increasing adverse reactions, making it a promising approach for clinical application.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.